The objective of this article was to study the re producibility and effect of levodopa on dopamine transporter function measurements using 213-carbomethoxy-313-( 4-[ 18F]_ fluorophenyl)tropane ([18F]CFT) positron emission tomogra phy (PET), Seven de novo patients with Parkinson' s disease (PD) were studied twice, before and after three months of levo dopa medication. Eight healthy volunteer subjects participated in the reproducibility study. The [18F]CFT PET scan was done twice with an interval of approximately 2.5 months. The re gions of interest (anterior and posterior putamen, caudate nucleus, and cerebellum) were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET im ages, and copied onto the PET images. The [18F]CFT uptake was calculated as the region-cerebellum:cerebellum ratio at 180 to 210 minutes. Three-month levodopa treatment in PD patients had no significant effect on [18F]CFT uptake in any striatal subregion between the two PET scans. In PD patients,
Progressive loss of nigrostriatal dopaminergic neurons is the basic pathophysiologic mechanism of Parkinson' s disease (PD), Positron emission tomography (PET) or single photon emission computed tomography (SPECT) has demonstrated this reduced dopaminergic function in vivo using 6-[ 18 F]fluoro-L-dopa (FDOPA; Boyes et aI., 1986; Brooks et aI., 1990) (Rinne et aI., 1999) .
Positron emission tomography and SPECT are in creasingly used in studying the progression of nigrostri-the percent change from baseline was 4.1 % in the anterior putamen, 1.9% in the posterior putamen, and 4.0% in the cau date nucleus. No significant differences in eSF]CFT uptake between the first and second PET scan in any striatal subregion occurred in healthy controls. The intraclass correlation, indi cating the reproducibility of the PET scan within subjects, was 0.94 for the anterior putamen, 0.86 for the posterior putamen, and 0.91 for the caudate nucleus. The percent change from baseline was 4.0% in the anterior putamen, 1.1 % in the poste rior putamen, and 2.8% in the caudate nucleus. Long-term levo dopa treatment in PD patients had no effect on the [18F]CFT uptake in the striatum and the test-retest reproducibility was very high. These findings confirm [18F]CFT as a suitable ligand to monitor progression of PD. Key Words: CFT-Parkinson's disease-Positron emission tomography-Reproduc ibility-Test-retest.
atal dopaminergic hypofunction and the neuroprotection in PD, There are a few PET studies using FDOPA as a ligand (Vingerhoets et aI., 1994; Leenders et a!., 1998; Morrish et aI., 1998; Nurmi et aI., 1999) , In these studies, the rate of annual decline in tracer uptake was approxi mately 8% to 10% in the putamen and 3,5% (Morrish et aI., 1998) or 6.6% (Nurmi et aI., 1999) in the caudate nucleus, or, using a different method of analysis, 1.7% in the total striatum (Vingerhoets et aI., 1994) . With [ 123 I][3-CIT, an annual rate of decline of 11.8% was found in the total striatum (Marek et aI., 1998) , and a [ 18 F]CFT PET study showed an annual rate of decline of the baseline mean of 13. J % in the putamen and 12.5% in the caudate nucleus (Nurmi et aI., 2000) .
In studying the progression in PD it is important to know the test-retest reproducibility of PET or SPECT measurements in the same individuals when doing serial scannings, In a study with [ 123 I][3-CIT SPECT, the test-retest variability of striatal V3" was 16.8% ± 13.3% for PD patients and 12.8% ± 8.9% for healthy controls (Seibyl et aI., 1997) . The measure V3" is directly related to the binding potential defined as num ber of binding sites divided by the dissociation constant (Bmax/Kd).
Another important issue is medication because pa tients are usually without anti parkinsonian medication at the first scan, whereas patients are on various medi cations, primarily levodopa treatment, at the time of the subsequent scan. For ethical reasons, it is impossible to study the progression in PD for a longer period without allowing the patients their medication. With r 123 1] f3-CIT SPECT, no significant difference among PD patients in dopamine transporter ligand uptake was found before and after 4 to 6 weeks treatment of L-dopa and carbidopa or L-selegiline (Innis et aI., 1999) . In a [ 123 I]f3-CIT SPECT study with baboons, infusion of a high dose of L-dopa had no effect on the dopamine transporter ligand binding (Laruelle et aI., 1993) .
The purpose of the current study was to evaluate the usefulness of a dopamine transporter PET ligand, [ 18 F]CFT, in monitoring progression and treatment effects in PD. Therefore, the authors studied the effect of levodopa treatment on [ 18 F]CFT uptake and the nor mal variation of test�retest [ 18 F]CFT PET in healthy controls.
MATERIALS AND METHODS

Subjects
The authors studied 7 de 1101'0 patients with PD (6 women, I man). Patients were diagnosed and treated at the Department of Neurology, University of Turku, Finland. The patients had at least 2 of the 3 cardinal features of PD: resting tremor. rigidity, or hypokinesia. In addition, no atypical features (Hughes et aI., 1993) were seen. The disability of the patients was eval uated by the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). The mean UPDRS motor score was 31 .1 ± 4.8 (mean ± SD, range 23 to 38). The Hoehn and Yahr stage was two for all of the patients. The mean age of the patients was 66.6 ± 8.5 years (mean ± SD) with a range of 51 to 73 years, and the mean duration of the symptoms (±SD) was 2.5 ± 0.9 years (range 1.2 to 3.7 years) at the time of first PET scan. The patients were not taking antiparkinsonian medication at the time of the first PET scan. Levodopa treat ment was started thereafter with a favorable effect. The pa tients were scanned twice, before medication and after three months of levodopa treatment. The patients were given levo dopa and carbidopa or levodopa and benserazide and the dose of levodopa was raised individually, that is, 200 mg to 400 mg per day at the time of the second PET scan. The levodopa treatment was stopped at least 6 hours before the PET scan.
Eight healthy volunteer subjects (5 women, 3 men) with a mean age of 54.5 ± 9.3 (range 40 to 70) years and no history or evidence of neurologic or psychiatric diseases wcre evaluated in the reproducibility study. The subjects were scanned twice approximately 2.5 months apart.
In addition to the PET scan, all patients underwent a 1.5 Tesla MRI, which was interpreted by an experienced neuroradiologist and no abnormalities were found. The MRI scan was used in the region of interest analysis (see Regions of interest).
The current study was approved by the Joint Ethical Com mittee of Turku University and Turku University Central Hos pital. A written informed consent form was signed by each subject.
Radiochemistry
[,sF]CFT (or [,sF]WIN 35,428) (Haaparanta et aI., 1996) was synthesized by electrophilic fluorination of 213carbomethoxy -313-( 4-trimethy Istanny I pheny I )tropane (Berg man ct aI., 1997). The precursor was dissolved in 700 fLL Freon-II and 100 fLL acetic acid, after which high specific radioactivity electrophilic r 1 xF]fluorine was bubbled through the mixture. The [18F]CFT formed was isolated with prepara tive HPLC, the eluent evaporated, and the residue dissolved in a saline and phosphate buffer solution. The electrophilic [,8F]t1uorine was synthesized from [18F]fluoride according to the method developed at the authors' laboratory (Bergman and Solin, 1997) . The radiochemical purity exceeded 98% and the specific radioactivity at the end of synthesis was 12.5 ± 3.1 GBq/fLmol.
PET imaging
Positron emission tomography scans were performed with the GE Advance PET scanner (General Electric Medical Sys tems, Milwaukee, WI, U.S.A.) in the two-dimensional scan ning mode. Briefly, the transaxial spatial resolution full width at half maximum at a radius of 10 cm in midplanes was ap proximately 5 mm axially and transaxially. The subjects were positioned in the scanner with three-dimensional laser align ment with reference to the orbito-meatal line. On average, at the first PET scan, 156 ± 27 MBq, and at the second PET scan, 144 ± 33 MBq of [18F]CFT was injected intravenously corre sponding to a mean injected mass of 4.8 fLg (SD = 0.8, range 3.4 to 6.1 fLg). A 60-minute PET scan was performed ISO minutes after injection.
Regions of interest
The regions of interest were identified and drawn on the head of the caudate, anterior and posterior putamen, and cerebellum on both hemispheres on 1.5 Tesla MRI images that were matched with the PET images using the surface fitting method (Pcllizari et aI., 1989) and resliced according to PET images using trilinear interpolation. The root mean squarc misfit of MRI�PET fitting was 1.83 mm (Pellizari et aI., 1989) . The heads of the caudate and anterior and posterior putamen were located on two consecutive planes. The regions of interest were then copied onto the PET images that had been matched with PET images as de scribed above. The average of the radioactivity concentra tions of the anterior and posterior putamen and caudate nu cleus in these two planes was then calculated. The cere bellum was used as reference in the analysis because it contains a negligible amount of dopamine and dopamine receptors. The uptake of [18F]CFT was calculated as the regioncerebellum: cerebellum ratio at 180 to 21 0 minutes (Laakso et aI., 1998; Rinne et aI., 1999) . The means of the corresponding left and right hemisphere regions on inter est values were averaged before statistical analyses were performed.
Statistics
Descriptive statistics, means, and standard deviations were used to assess subjects' age, duration of symptoms, and the different regions of interest (caudate and anterior and posterior putamen).
The intraclass correlation coefficients for each region were calculated for PD patients and healthy controls to evaluate the reliability of the replicated measurements. Standard deviations within subjects in both groups were estimated with a linear model of two repeated measurements (scanl and scan2). In addition, percent changes calculated as the difference between scan 1 and scan2 measurements divided by the scan I measure ment were used to quantify the magnitude of the variation within the subjects.
Repeated measurements analysis of variance with treat ment as a between-factor and region as a within-factor was used to analyze the changes between scan 1 and scan2 mea surements. Bonferroni-adjustement was applied when neces sary to overcome the multiplicity problem. All statistical analyses were performed with PROC MIXED in SAS (Ver sion 6. 12; SAS Institute, Cary, NC, U.S.A.) with subjects treated as a random effect. For the covariance structure, a compound symmetry was selected. The estimation was per formed with the restricted estimation maximum likelihood method. A two-sided P value < 0.05 was considered statisti cally significant.
RESULTS
Effect of levodopa
In PD patients, the mean e S F]CFT uptake ratio was reduced in the anterior putamen to 42.5% (P < 0.0001), in the posterior putamen to 26.6% (P < 0.0001), and in the caudate to 67.3% (P = 0.001) from the control mean ratio. The absolute [ ls F]CFT uptake ratio values at the time of the first and second PET scan are shown in Table 1 . In PD patients, the 3-month levodopa treat-ment had no significant effect on dopamine trans porter function because the e S F]CFT uptake was not significantly changed in any striatal subregion between the two PET scans (P = 1.0 in the anterior and pos terior putamen and in the caudate nucleus, after Bonfer roni-adjustement to multiple comparisons). The intra class correlation, indicating the reproducibility of the PET scan within subjects, was high at 0.97, 0.95, and 0.96 for the anterior putamen, posterior putamen, and caudate nucleus, respectively. The high intraclass correlation indicates that the variation within subjects is small compared with the variation between subjects. The percent change calculated as the difference be tween scanl and scan2 measurements divided by the scan l measurement ranged from 1.9% to 4.1 %. In PD patients, the scan-to-scan intrasubject standard devia tion varied from 3.7% to 6.3% ( Table I) . Figure 1 shows individual [ 18 F]CFT uptake values in PD pa tients and controls at scan 1 and scan2 in striatal subregions.
The mean motor UPDRS score decreased from 31.1 (SD = 4.8) at scanl to 21.1 (SD = 5.0) at scan2 during the 3-month levodopa treatment. The difference (mean = 10.0, SD = 3.1) between the motorUPDRS scores at scanl and scan2 was highly statistically significant (P = 0.0014, one-sample t-test).
Reproducibility
In healthy controls, there were no significant statistical differences in [ 18 F]CFT uptake between the first and sec ond PET scans in any striatal subregion (P = 0.09, 1.0, and 0.57 in the anterior putamen, posterior putamen, and Ratio, region--cerebellum:cerebellum; change (%), (scanl-scan2)/scanl x 100%; SDW. standard deviation within subjects; R, intraclass correlation coefficient. caudate nucleus, respectively, after Bonferroni adjustement to multiple comparisons). The reproducibil ity of [ 18 F]CFT uptake values was also calculated using the intraclass correlation coefficient, which was 0.94 for the anterior putamen, 0.86 for the posterior putamen, and 0.91 for the caudate nucleus, indicating good reproduc ibility. The percent change calculated as the difference between scanl and scan2 measurements divided by the scanl measurement varied from 1.1 % to 4.09'0. In healthy controls, the within-subject standard deviation values ranged from 4.4% to 8.1 % ( Table I) .
The repeated measurements analysis of variance showed no significant difference in the change of [ ,s F]CFT uptake ratios between the two scans between PD patients and healthy controls in any striatal subregion (P = 0.75). This further indicates that levodopa treat ment had no significant effect on [ 18 F]CFT uptake in PD patients.
DISCUSSION
The current study shows good reproducibility of do pamine transporter PET ligand [ ls FlCFT uptake mea sured by the region-cerebellum:cerebellum ratio. The high intraclass correlation coefficient found indicates that the variation within subjects is small compared with the variation between subjects. This was true for healthy controls and PD patients. Moreover, the small percent change between the two PET scans, and the low within-subject standard deviation (scan-to scan intrasubject standard deviation) indicate good reproducibility.
The authors found no significant effect of 3-month levodopa therapy on [ I g F]CFT binding in any striatal subregion in patients with PD. In a previous [ 123 I]�_CIT SPECT study, PD patients were given a subchronic treat ment of 4 to 6 weeks of L-dopa and carbidopa and no significant effect of L-dopa treatment on dopamine transporter ligand binding was found in the striatum (In nis et a!., 1999). These findings in PD patients are in agreement with animal studies. In a [ 123 I]�_CIT SPECT study with baboons, intravenous infusion of L-dopa had no acute effect on [ 123 1] �-CIT binding in the striatum (Laruelle et a!., 1993) . In addition, in rats, 2 weeks of treatment with L-dopa and benserazide did not affect striatal dopamine transporter binding evaluated by [ 3 H]CFT (Vander Borght et a!., 1995) . However, this finding in rats with intact nigrostriatal system does not necessarily reflect the situation in PD patients. The current results extend the previous findings by showing that even the 3-month levodopa therapy had no sig nificant effect on dopamine transporter function studied by [ 18 F]CFT PET. Taken together, these findings indi cate that in studies of progression of PD the decline found in dopamine transporter ligand uptake is not be cause of the levodopa effect. However, it is possible that changes may take place even after 3 months of treat ment; but this is unlikely because levodopa already would have achieved the steady-state level after 6 weeks of treatment (Innis et a!., 1999) . In addition, the levodopa dose that the authors' administered to their patients was small, but was titrated according to clinical re sponse. The decrease in the mean motor UPDRS motor score (3l .1 at baseline vs. 2l .1 at scan2) indicates that the dose used was adequate. However, the possibility remains that high doses of levodopa may have some effect, although this is unlikely because even high-dose L-dopa (50 mg/kg intravenously) did not affect dopa mine transporter binding in nonhuman primates (La ruelle et ai., 1993).
One particular consequence of the unchanged e 8 F]CFT uptake on levodopa treatment is that the pa tients need not cease taking levodopa long before the scan. In the current study levodopa treatment was stopped six hours before the PET scan. The low variation from scan-to-scan in healthy controls and PD patients enables detection of even small effects of various drugs on dopamine transporter function.
In a SPECT study with e 23 I] [3-CIT, uptake values showed a 12.8% test-retest variability of striatal V3" in healthy subjects (Seibyl et ai., 1997) . The corresponding figure for e S F]CFT PET found in the current study was considerably lower (varying from 1.1 % to 4.0% in con trols). There was a slight difference in the method for calculating the variability. In the [ l23 I] [3-CIT SPECT study (Seibyl et ai., 1997) , percent striatal uptake within subjects was measured as the absolute value of the dif ference of the test and retest measure divided by the mean of test and retest and expressed as a percentage. In contrast, in the current study, percent change was calcu lated as the difference between scan I and scan2 mea surements divided by the scan I measurement. This small methodological difference can not explain the variation between these two studies because in the current controls the e S F]CFT uptake ratios were almost the same at the two PET scans. Thus, using either the mean of the scan 1 and scan2 values or the scan I value as a divisor, the result would essentially be the same. The better sensitiv ity and resolution of PET compared with SPECT, and also the use of anatomic reference (MRI) in the current study are factors contributing to this difference in the test-retest variability.
In previous studies of progression in PD, the annual rate of decline in dopamine transporter ligand uptake has been much greater than the test-retest variability found in the current study. In a e S F]CFT PET study, the annual rate of decline of the baseline mean was 13.1 % in the putamen and 12.5% in the caudate nucleus (Nurmi et ai., 2000) . This is in agreement with the [ l23 I][3-CIT SPECT study in which the annual rate of decline of tracer uptake was 11.8% in the total striatum (Marek et ai., 1998).
Thus, dopamine transporter ligands are sensitive both to detecting dopaminergic hypofunction in PD and to moni toring its progression.
The current findings indicate good reproducibility of measuring dopamine transporter function in normal con trols and patients with PD. Moreover, levodopa treat ment does not have a significant effect on dopamine transporter ligand binding in PD. Therefore, dopamine J Cereb Blood Flow Metab, Vol. 20, No. J J, 2000 transporter ligands are feasible in studies of disease pro gression of PD.
